Design Therapeutics is set to present significant safety findings from its Phase 1 trial of DT-168, highlighting progress in their clinical development for treating Fuchs endothelial corneal dystrophy ...
A newer technique for preparing corneal tissue for transplantation has been shown to be safe and effective, while providing a faster and smoother process than the traditional technique, according to ...
CARLSBAD, Calif., April 24, 2023 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today ...
Design Therapeutics Inc. has described transcription modulators reported to be useful for the treatment of myotonic dystrophy type 1 (DM1) and Fuchs’ dystrophy.
This story is part of a series on the current progression in Regenerative Medicine. This piece is part of a series dedicated to the eye and improvements in restoring vision. In 1999, I defined ...
A retired lecturer from Edinburgh will be able to see Christmas properly for the first time in years after receiving a ...
David Watkins, 72, from Edinburgh had to sit in the dark and wear sunglasses all the time before he underwent surgery which ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback